

Matthew R. Orr, Bar No. 211097
 morr@calljensen.com
 William P. Cole, Bar No. 186772
 wcole@calljensen.com
 Joshua G. Simon, Bar No. 264714
 jsimon@calljensen.com
 CALL & JENSEN
 A Professional Corporation
 610 Newport Center Drive, Suite 700
 Newport Beach, CA 92660
 Tel: (949) 717-3000
 Fax: (949) 717-3100

Geoffrey W. Castello [*Admitted Pro Hac Vice*]
 Glenn T. Graham [*Admitted Pro Hac Vice*]
 KELLEY DRYE & WARREN LLP
 One Jefferson Road, 2nd Floor
 Parsippany, NJ 07054
 Tel: (973) 503-5900
 gcastello@kelleydrye.com
 ggraham@kelleydrye.com
 Attorneys for Defendant
 Quincy Bioscience, LLC

Attorneys for Defendant Quincy Bioscience, LLC

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

PHILLIP RACIES, On Behalf of Himself
 and All Others Similarly Situated,

Plaintiff,

vs.

QUINCY BIOSCIENCE, LLC, a
 Wisconsin limited liability company,

Defendant.

Case No. 4:15-cv-00292 HSG

AMENDED JOINT EXHIBIT LIST

Date: January 6, 2020
 Time: 8:30 a.m.
 Place: Courtroom 2

Complaint Filed: January 21, 2015
 Trial Date: January 6, 2020

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
1	Stipulated Fact Exhibit (to be completed by the Parties)			
2	Racies Retention Letter	Racies, Phillip		
3	Plaintiff Racies' Walgreens Receipt	Racies, Phillip		
4	GRAS Notice (GRN) No. 568	Underwood, Mark Moran, Daniel Corporate Representative		
5	Withdrawn			
6	Withdrawn			
7	Withdrawn			
8	Withdrawn			
9	Withdrawn			
10	Withdrawn			
11	Withdrawn			
12	Aalberse RC. Structural biology of allergens. J Allergy Clin Immunol 2000;106:228-38.	Bazinet, Richard Bisordi, William		
13	Abeyrathne ED, Lee HY, Ahn DU. Egg white proteins and their potential use in food processing or as nutraceutical and pharmaceutical agents--a review. Poult Sci 2013;92:3292-9.	Bazinet, Richard Bisordi, William		
14	Abeyrathne ED, Lee HY, Ahn DU. Sequential separation of lysozyme, ovomucin, ovotransferrin, and ovalbumin from egg white. Poult Sci 2014;93:1001-9.	Bazinet, Richard Bisordi, William		
15	Astwood JD, Leach JN, Fuchs RL. Stability of food allergens to digestion in vitro. Nat Biotechnol 1996;14:1269-73.	Bazinet, Richard Bisordi, William		
16	Bannon GA, Goodman RE, Leach JN, Rice E, Fuchs RL, Astwood JD. Digestive Stability in the Context of Assessing the Potential Allergenicity of Food Proteins. Comments on Toxicology 2002;8:271-85.	Bazinet, Richard Goodman, Richard		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
17	Boron WF, Boulpaep EL. Medical physiology: a cellular and molecular approach: Elsevier Saunders; 2005, Chapter 44 Nutrient Digestion and Absorption	Bazinet, Richard		
18	Butts CA, Monro JA, Moughan PJ. In vitro determination of dietary protein and amino acid digestibility for humans. The British journal of nutrition 2012;108 Suppl 2:S282-7	Bazinet, Richard		
19	Castell JV, Friedrich G, Kuhn CS, Poppe GE. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol 1997;273:G139-46.	Bazinet, Richard Bisordi, William		
20	Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MG, Tsao JW. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging 2012;29:259-73.	Bazinet, Richard		
21	Commission. CA. Alinorm 03/34: Joint FAO/WHO Food Standard Programme, Codex Alimentarius Commission, Twenty-Fifth Session, Rome, Italy 30 June-5 July, 2003. Appendix III, Guideline for the conduct of food safety assessment of foods derived from recombinant-DNA plants and Appendix IV, Annex on the assessment of possible allergenicity 2003.	Bazinet, Richard		
22	Cunnane S, Nugent S, Roy M, et al. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 2011;27:3-20.	Bazinet, Richard		
23	Dembo G, Park SB, Kharasch ED. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005;102:409-15.	Bazinet, Richard		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
24	Deng L, Vysotski ES, Markova SV, et al. All three Ca ²⁺ -binding loops of photoproteins bind calcium ions: the crystal structures of calcium-loaded apo-aequorin and apo-obelin. Protein Sci 2005;14:663-75.	Bazinet, Richard Bisordi, William		
25	Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet 2013;52:855-68.	Bazinet, Richard		
26	Excerpts of Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients): The National Academies Press; 2005. Summary, Chapter 1 (Introduction to Dietary Reference Intakes) and Chapter 10 (Protein and Amino Acids).	Bazinet, Richard		
27	Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:311-21.	Bazinet, Richard		
28	Erickson RH, Kim YS. Digestion and absorption of dietary protein. Annu Rev Med 1990;41:133-9.	Bazinet, Richard		
29	Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Annals of the New York Academy of Sciences 2012;1258:25-33.	Bazinet, Richard		
30	Frazer DM, Darshan D, Anderson GJ. Intestinal iron absorption during suckling in mammals. Biometals 2011;24:567-74.	Bazinet, Richard Bisordi, William		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
31	Freund Levi Y, Vedin I, Cederholm T, et al. Transfer of omega-3 fatty acids across the bloodbrain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. J Intern Med 2014;275:428-36.	Bazinet, Richard		
32	Fu TJ, Abbott UR, Hatzos C. Digestibility of food allergens and nonallergenic proteins in simulated gastric fluid and simulated intestinal fluid-a comparative study. Journal of agricultural and food chemistry 2002;50:7154-60.	Bazinet, Richard		
33	Gardner ML. Gastrointestinal absorption of intact proteins. Annu Rev Nutr 1988;8:329-50.	Bazinet, Richard Bisordi, William		
34	Gilani GS, Xiao C, Lee N. Need for accurate and standardized determination of amino acids and bioactive peptides for evaluating protein quality and potential health effects of foods and dietary supplements. J AOAC Int 2008;91:894-900.	Bazinet, Richard		
35	Hartmann R, Meisel H. Food-derived peptides with biological activity: from research to food applications. Curr Opin Biotechnol 2007;18:163-9.	Bazinet, Richard		
36	Head JF, Inouye S, Teranishi K, Shimomura O. The crystal structure of the photoprotein aequorin at 2.3 Å resolution. Nature 2000;405:372-6.	Bazinet, Richard		
37	Heyman M, Ducroc R, Desjeux JF, Morgat JL. Horseradish peroxidase transport across adult rabbit jejunum in vitro. Am J Physiol 1982;242:G558-64.	Bazinet, Richard Bisordi, William		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
38	Heyman M, Abed J, Lebreton C, Cerf-Bensussan N. Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis. Gut 2012;61:1355-64.	Bazinet, Richard Bisordi, William		
39	Hsuchou H, Pan W, Kastin AJ. The fasting polypeptide FGF21 can enter brain from blood. Peptides 2007;28:2382-6.	Bazinet, Richard		
40	Jeong HJ, Lee JR, Jeong JB, Park JH, Cheong YK, de Lumen BO. The cancer preventive seed peptide lunasin from rye is bioavailable and bioactive. Nutr Cancer 2009;61:680-6.	Bazinet, Richard Bisordi, William		
41	Jeong HJ, Jeong JB, Hsieh CC, Hernandez-Ledesma B, de Lumen BO. Lunasin is prevalent in barley and is bioavailable and bioactive in in vivo and in vitro studies. Nutr Cancer 2010;62:1113-9.	Bazinet, Richard Bisordi, William		
42	Jones K, Hibbert F, Keenan M. Glowing jellyfish, luminescence and a molecule called coelenterazine. Trends Biotechnol 1999;17:477-81.	Bazinet, Richard		
43	Jumpertz R, Guijarro A, Pratley RE, Mason CC, Piomelli D, Krakoff J. Associations of fatty acids in cerebrospinal fluid with peripheral glucose concentrations and energy metabolism. PLoS One 2012;7:e41503.	Bazinet, Richard		
44	Kazdin AE. The meanings and measurement of clinical significance. J Consult Clin Psychol 1999;67:332-9.	Bazinet, Richard		
45	Kharitonov A, Larsen P. FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab 2011;22:81-6.	Bazinet, Richard		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
46	Maccio A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist 2010;15:894-902.	Bazinet, Richard		
47	Madara JL. Regulation of the movement of solutes across tight junctions. Annu Rev Physiol 1998;60:143-59.	Bazinet, Richard		
48	Matthews DM, Laster L. Absorption of protein digestion products: a review. Gut 1965;6:411-26.	Bazinet, Richard		
49	Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci 2001;58:1234-45.	Bazinet, Richard Bisordi, William		
50	Mobasheri A. Glucose: an energy currency and structural precursor in articular cartilage and bone with emerging roles as an extracellular signaling molecule and metabolic regulator. Front Endocrinol (Lausanne) 2012;3:153.	Bazinet, Richard		
51	Moran DL, Marone PA, Bauter MR, Soni MG. Safety assessment of Apoaequorin, a protein preparation: subchronic toxicity study in rats. Food Chem Toxicol 2013;57:1-10.	Bazinet, Richard		
52	Ofori-Anti AO, Ariyaratna H, Chen L, Lee HL, Pramod SN, Goodman RE. Establishing objective detection limits for the pepsin digestion assay used in the assessment of genetically modified foods. Regul Toxicol Pharmacol 2008;52:94-103.	Bazinet, Richard Goodman, Richard		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
53	Ortiz-Martinez M, Winkler R, Garcia-Lara S. Preventive and therapeutic potential of peptides from cereals against cancer. J Proteomics 2014;111:165-83.	Bazinet, Richard Bisordi, William		
54	Paganelli R, Levinsky RJ. Solid phase radioimmunoassay for detection of circulating food protein antigens in human serum. J Immunol Methods 1980;37:333-41.	Bazinet, Richard Pezzone, Michael		
55	Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 2002;1:131-9.	Bazinet, Richard		
56	Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2:3-14.	Bazinet, Richard		
57	Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. Journal of neurochemistry 1998;70:1781-92.	Bazinet, Richard		
58	Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32:1959-72.	Bazinet, Richard		
59	Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 2012;503:269-92.	Bazinet, Richard		
60	Park JW, Kim SJ, Kwag DS, et al. Multifunctional Delivery Systems for Advanced oral Uptake of Peptide/Protein Drugs. Curr Pharm Des 2015;21:3097-110.	Bazinet, Richard		
61	Pizzorno J. Zonulin! The wheat conundrum solved (well, mostly ...). Altern Ther Health Med 2014;20 Suppl 1:10-5.	Bazinet, Richard		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
62	Price DB, Ackland ML, Burks W, Knight MI, Suphioglu C. Peanut allergens alter intestinal barrier permeability and tight junction localisation in Caco-2 cell cultures. Cell Physiol Biochem 2014;33:1758-77.	Bazinet, Richard Bisordi, William		
63	Rapoport SI, Klee WA, Pettigrew KD, Ohno K. Entry of opioid peptides into the central nervous system. Science 1980;207:84-6.	Bazinet, Richard		
64	Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322-33.	Bazinet, Richard		
65	Schnell S, Herman RA. Should digestion assays be used to estimate persistence of potential allergens in tests for safety of novel food proteins? Clin Mol Allergy 2009;7:1.	Bazinet, Richard		
66	Shils ME, J.A. O, Shike M. Modern nutrition in health and disease: Lea and Febiger; 1994, Chapter 1 Proteins and Amino Acids (Crim and Munro)	Bazinet, Richard		
67	Shimomura O, Johnson FH, Saiga Y. Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea. J Cell Comp Physiol 1962;59:223-39.	Bazinet, Richard		
68	Singh BP, Vij S, Hati S. Functional significance of bioactive peptides derived from soybean. Peptides 2014;54:171-9.	Bazinet, Richard Bisordi, William		
69	Tahara T, Usuki K, Sato H, et al. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol 1996;93:783-8.	Bazinet, Richard		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
70	Takano M, Koyama Y, Nishikawa H, Murakami T, Yumoto R. Segment-selective absorption of lysozyme in the intestine. European journal of pharmacology 2004;502:149-55.	Bazinet, Richard Bisordi, William		
71	Tvarijonaviciute A, Martinez-Subiela S, Ceron JJ. Validation of 2 commercially available enzyme-linked immunosorbent assays for adiponectin determination in canine serum samples. Can J Vet Res 2010;74:279-85	Bazinet, Richard		
72	Walker WA, Cornell R, Davenport LM, Isselbacher KJ. Macromolecular absorption. Mechanism of horseradish peroxidase uptake and transport in adult and neonatal rat intestine. J Cell Biol 1972;54:195-205.	Bazinet, Richard Bisordi, William Pezzone, Michael		
73	Yokooji T, Hamura K, Matsuo H. Intestinal absorption of lysozyme, an egg-white allergen, in rats: kinetics and effect of NSAIDs. Biochemical and biophysical research communications 2013;438:61-5.	Bazinet, Richard Pezzone, Michael		
74	Yokooji T, Nouma H, Matsuo H. Characterization of ovalbumin absorption pathways in the rat intestine, including the effects of aspirin. Biol Pharm Bull 2014;37:1359-65.	Bazinet, Richard Bisordi, William		
75				
76	Apoaequorin and the Blood Brain and Gastrointestinal Barriers	Underwood, Mark		
77	Quantification of Apoaequorin from Dog CSF and Plasma Samples (Custom Biologics)	Underwood, Mark		
78	Defining the meaning of allergenicity test results - What the data does and does not show.	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
79	Ehlers, V.L., Adams, E.L., Fettingner, N.B., Michels, S.C., Moyer, J.R., The neurotherapeutic effects of the calcium binding protein apoaeguorin	Underwood, Mark Moran, Daniel Corporate Representative		
80	Development of an Enzyme-Linked Immunosorbent Assay (ELISA) and Electrochemiluminescent (ECL) – based Assay for the Quantification of Apoaeguorin in Biological Matrices for Quincy Bioscience	Underwood, Mark		
81	Milgram, N., Landsberg, G., Merrick, D., Underwood, M., A novel mechanism of cognitive enhancement in aged dogs with the use of a calcium-buffering protein, Journal of Veterinary Behavior 10 (2015) 217-222	Underwood, Mark		
82	Orally administered apoaeguorin protects neurons frm oxygen-glucose deprivation (presentation)	Underwood, Mark Moran, Daniel Corporate Representative		
83	Intestinal Absorption of Intact Proteins, Qunicy Bioscience, LLC, D. Moran, PhD	Underwood, Mark		
84	Report on bioinformatics analysis	Underwood, Mark Moran, Daniel Corporate Representative		
85	Report on allergenicity study	Underwood, Mark		
86	Moran DL, Tetteh AO, Goodman RE, Underwood MY. Safety assessment of the calciumbinding protein, apoaeguorin, expressed by Escherichia coli. Regul Toxicol Pharmacol 2014;69:243-9.	Underwood, Mark Goodman, Richard		
87	Orally administered apoaeguorin protects neurons frm oxygen-glucose deprivation (presentation)	Underwood, Mark		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
88	Amini, A., Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy. Journal of Experimental & Clinical Cancer Research 2014, 33:92	Bisordi, William		
89	Chuang, E., Calcium depletion-mediated protease inhibition and apical-junctional-complex disassembly via an EGTA-conjugated carrier for oral insulin delivery. Journal of Controlled Release 169 (2013) 296-305	Bisordi, William		
90	Shimizu, H., A case of serratiopeptidase-induced subepidermal bullous dermatosis. British Association of Dermatologists, British Journal of Dermatology. 1999. 141 , 1136-1153	Bisordi, William		
91	Polovic., N., A matrix effect in pectin-rich fruits hampers digestion of allergen by pepsin in vivo and in vitro. Clinical and Experimental Allergy, 37, 764-771	Bisordi, William		
92	Sumi, H., A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia. 1987 Oct 15;43(10):1110-1	Bisordi, William		
93	Shetty, V., A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Comparing the Efficacy of Systemic Enzyme Therapy for Edema Control in Orthognathic Surgery Using Ultrasound Scan to Measure Facial Swelling. J Oral Maxillofac Surg. 2013 Jul;71(7):1261-7	Bisordi, William		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
94	Choonara, B. F., A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnology Advances 32 (2014) 1269-1282	Bisordi, William		
95	Muheem, A., A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharmaceutical Journal. (2014) 1-16	Bisordi, William		
96	Ye, J., A role for intracellular calcium 111 tight junction reassembly after ATP depletion repletion. Am J Physiol. 1999 Oct; 277(4 Pt 2):F524-32	Bisordi, William		
97	Kurosawa, Y., A single-dose of oral nattokinase potentiates thrombolysis and anticoagulation profiles. Sci Rep. 2015 Jun 25;5:11601	Bisordi, William		
98	Gardner, M. L. G., Absorption of Intact Peptides: Studies on Transport of Protein Digests and Dipeptides Across Rat Small Intestine. Quarterly Journal of Experimental Physiology (1982) 67, 629-637	Bisordi, William		
99	Abd el Dayem, S. M., Alpha-chymotrypsin ameliorates neuroinflammation and apoptosis characterizing Alzheimer's disease-induced in ovariectomized rats. Experimental and Toxicologic Pathology 65 (2013) 477- 483	Bisordi, William		
100	Hsu, R., Amyloid-Degrading Ability of Nattokinase from Bacillus subtilis Natto. J. Agric. Food Chem. 2009, 57, 503-508	Bisordi, William		
101	Pali- Scholl, I., Antacids & Dietary Supplements with an Influence on the Gastric pH Increase the Risk for Food Sensitization. Clin Exp Allergy. July 2010. 40(7): 1091-98	Bisordi, William		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
102	Martfnez-Maqueda, D., Antihypertensive peptides from food proteins: a review. Food Funct. 2012 Apr;3(4):350-61	Bisordi, William		
103	Kim, S., Bioactive Compounds from Marine Sponges and Their Symbiotic Microbes: A Potential Source of Nutraceuticals. Adv Food Nutr Res. 2012;65:137-51	Bisordi, William		
104	Agyei, D., Bioactive Proteins and Peptides from Soybeans. Recent Pat Food Nutr Agric. 2015;7(2): 100- 7.	Bisordi, William		
105	Walther, B., Bioactive Proteins and Peptides in Foods. Int. J. Vitam. Nutr . Res., 81 (2- 3), 2011, 181-191	Bisordi, William		
106	Ngo, D., Biological activities and potential health benefits of bioactive peptides derived from marine organisms. International Journal of Biological Macromolecules 51 (2012) 378- 383	Bisordi, William		
107	Soares de Castro, R., Biologically active peptides: Processes for their generation, purification and identification and applications as natural additives in the food and pharmaceutical industries. Food Research International 74 (2015) 185-198	Bisordi, William		
108	Montagne, A., et al., Blood-brain barrier breakdown in the aging human hippocampus. Neuron, 2015. 85(2): p. 296-302	Bisordi, William Spencer, Brian		
109	Alafuzoff, I., Blood-brain barrier in Alzheimer dementia and in non-demented elderly. Acta Neuropathol (Berl) (1987) 73:160-166	Bisordi, William		
110	van de Haar, H.J., et al., Blood-brain barrier impairment in dementia: current and future in vivo assessments. Neurosci Biobehav Rev, 2015. 49: p. 71-81	Bisordi, William Spencer, Brian		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
111	Inouye, S., Blue fluorescent protein from the calcium-sensitive photoprotein aequorin is a heat resistant enzyme, catalyzing the oxidation of coelenterazine. FEBS Lett. 2004 Nov 5;577(1- 2):]05-10	Bisordi, William		
112	Arshad, Z. I. M., Bromelain: an overview of industrial application and purification strategies. Appl Microbial Biotechnol (2014) 98:7283-7297	Bisordi, William		
113	Pavan, R., Properties and Therapeutic Application of Bromelain: A Review. Hindawi Publishing Corporation. Biotechnology Research International. 2012: 1-6	Bisordi, William		
114	Bradley, P., Bromelain Containing Enzyme-Rutosid Combination Therapy is as Effective as Nonsteroidal Antiinflammatory Agents for Treatment of Osteoarthritis. School of Physician Assistant Studies. (2014) Paper 475	Bisordi, William		
115	Brown, R. C., Calcium Modulation of Adherens and Tight Junction Function A Potential Mechanism for Blood-Brain Barrier Disruption After Stroke. Stroke. 2002 ;33:1706-1711	Bisordi, William		
116	Szmola, R., Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: Identity with Rinderknecht's enzyme Y. Proc Natl Acad Sci U SA. 2007 Jul 3;104(27):11227- 32	Bisordi, William		
117	Freeman, H. J., Clinical relevance of intestinal peptide uptake. World J Gastrointest Pharmacol Ther 2015 May 6; 6(2): 22-27	Bisordi, William		

CALL & JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
118	Mouneshkumar, C. D., Comparison of clinical efficacy of methylprednisolone and serratiopeptidase for reduction of postoperative sequelae after lower third molar surgery. J Clin Exp Dent. 2015;7(2):e197-202	Bisordi, William		
119	Complementary and Alternative Medicine, Institute of Medicine (2005)	Bazinet, Richard Bisord, William		
120	De Bock, M., Connexin channels provide a target to manipulate brain endothelial calcium dynamics and blood-brain barrier permeability. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1942-1957	Bisordi, William		
121	Ettienne, E. M., Control of Contractility in Spirostomum by Dissociated Calcium Ions. J Gen Physiol. 1970 Aug;56(2):168-79	Bisordi, William		
122	Fouz, N., Cytokinetics Study on MCF-7 Cells Treated with Commercial and Recombinant Bromelain. Asian Pac J Cancer Prev. 2014 Jan; 14(1 1):6709-14	Bisordi, William		
123	Iadecola, C., Dangerous Leaks: Blood-Brain Barrier Woes in the Aging Hippocampus. Neuron. 2015 Jan 21;85(2):231-3	Bisordi, William		
124	He, W., Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability. International Journal of Pharmaceutics 495 (2015) 9- 18	Bisordi, William		
125	Jahan-Mihan, A., Dietary Proteins as Determinants of Metabolic and Physiologic Functions of the Gastrointestinal Tract. Nutrients 2011, 3, 574-603	Bisordi, William		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
126	Nakamura, S., Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. <i>Respirology</i> (2003) 8, 316-320	Bisordi, William		
127	RaviKumar, T., Effect of trypsin-chymotrypsin (Chymoral Forte D.S.) preparation on the modulation of cytokine levels in burn patients. <i>Burns</i> 27 (2001) 709-716	Bisordi, William		
128	Raiman, J., Effects of calcium and lipophilicity on transport of clodronate and its esters through Caco-2 cells. <i>International Journal of Pharmaceutics</i> 213 (2001) 135-142	Bisordi, William		
129	Amid, A., Effects of Operating Conditions in Spray Drying of Recombinant Bromelain. <i>Journal of Applied Science and Agriculture</i> , 9(20) Special 2014, Pages: 37-43	Bisordi, William		
130	De Bock, M., Endothelial calcium dynamics, connexin channels and blood-brain barrier function. <i>Progress in Neurobiology</i> 108 (2013) 1-20	Bisordi, William		
131	Sumi, H., Enhancement of the Fibrinolytic Activity in Plasma by Oral Administration of Nattokinase. <i>Acta Haematol.</i> 1990. 84:139-143	Bisordi, William		
132	Montgomery, K., Enzymes for Inflammation: Natural Proteolytic Enzymes Offer Relief from Pain and Swelling. <i>Natural Foods Merchandiser</i> ; Nov 2005; 26, 11	Bisordi, William		
133	Mazzone, A., Evaluation of Serratia Peptidase in Acute or Chronic Inflammation of Otorhinolaryngology Pathology: a Multicentre, Double-blind, Randomized Trial versus Placebo. <i>The Journal of International Medical Research</i> 1990; 18: 379 - 388	Bisordi, William		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
134	Geldenhuys , W. J., Evolution of a Natural Products and Nutraceuticals Course in the Pharmacy Curriculum. American Journal of Pharmaceutical Education 2015 ; 79 (6) Article 82	Bisordi, William		
135	Pansuriya, R. C., Evolutionary Operation (EVOP) to Optimize Whey-Independent Serratiopeptidase Production from Serratia marcescens NRRL B-23112. J. Microbial. Biotechnol. (2010), 20(5), 950-957	Bisordi, William		
136	Jasper, H., Exploring the physiology and pathology of aging in the intestine of Drosophila melanogaster. Invertebr Reprod Dev. 2015 Jan 30;59(supl):51-58	Bisordi, William		
137	Li, X., Expression and purification of recombinant nattokinase in Spodoptera frugiperda cells	Bisordi, William		
138	Casadei, J., Expression and secretion of aequorin as a chimeric antibody by means of a mammalian expression vector. Proc Natl Acad Sci US A. 1990 Mar;87(6):2047-51	Bisordi, William		
139	Udenigwe, C. C., Food Protein-Derived BioactivePeptides: Production, Processing, & Potential Health Benefits. J Food Sci. January 2012. 77(1): R1 1-24	Bisordi, William		
140	Korhonen , H., Milk-derived bioactive peptides: From science to applications. Journal of Functional Foods. 177-187	Bisordi, William		
141	George, S., Functional Characterization of Recombinant Bromelain of Ananas comosus Expressed in a Prokaryotic System. Mo! Biotechnol (2014) 56:166 - 174	Bisordi, William		
142	El Sohaimy, S.A., Functional Foods and Nutraceuticals-Modern Approach to Food Science. World Applied Sciences Journal 20 (5): 691-708, 2012	Bisordi, William		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
143	Singh, B. P., Functional significance of bioactive peptides derived from soybean. Peptides 54 (2014) 171-179	Bisordi, William		
144	Lorkowski, G. Gastrointestinal absorption and biological activities of serine and cysteine proteases of animal and plant origin: review on absorption of serine and cysteine proteases. Int. J Physiol Pathophysiol Pharmacol 2012; 4:10-27	Bisordi, William Pezzone, Michael		
145	Moreno, F. J., Gastrointestinal digestion of food allergens: Effect on their allergenicity. Biomedicine & Pharmacotherapy 61 (2007) 50-60	Bisordi, William		
146	Fioretti, E., Heterotropic modulation of the protease-inhibitor-recognition process Cations effect the binding properties of a-chymotrypsin. Eur. J. Biochem. 225,459-465 (1994)	Bisordi, William		
147	Zu, X., Thrombolytic Activities of Nattokinase Extracted from Bacillus Subtilis Fermented Soybean Curd Residues. International Journal of Biology. July 2010. 2 (2) 120-125	Bisordi, William		
148	Worthington, B.S., Boatman, E.S., and Kenny, G.E. Intestinal absorption of intact proteins in normal and protein-deficient rats. Am. J Clin. Nutr. 1974; 27:276-286	Bisordi, William Pezzone, Michael		
149	Worthington, B.S., Intestinal Permeability to Large Particles in Normal and Protein-Deficient Adult Rats. J. Nutr. 106: 20-32, 1976	Bisordi, William		
150	Wickham, M., In Vitro Digestion Methods for Assessing the Effect of Food Structure on Allergen Breakdown. Mo! Nutr Food Res. August 2009. 53(8): 952-58	Bisordi, William		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
151	Freitas, A. C., Marine biotechnology advances towards applications in new functional foods. Biotechnology Advances. November-December 2012. 30 (6) 15 06- 1 515	Bisordi, William		
152	Aleman, A., Marine collagen as a source of bioactive molecules. A review. Institute of Food Science, Technology and Nutrition (ICTAN-CSIC)**, Ciudad Universitaria, 28040	Bisordi, William		
153	Fasano, A., Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep;2(9):416- 22	Bisordi, William		
154	Ji, H., Mechanisms of Nattokinase in protection of cerebral ischemia. European Journal of Pharmacology. 745(2014)144-151	Bisordi, William		
155	Bell, R., Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 2009 July; 118(1): 103-113	Bisordi, William		
156	Fardet, A., New hypotheses for the health-protective mechanisms of whole-grain cereals: what is beyond fibre? Nutrition Research Reviews (2010), 23, 65-134	Bisordi, William		
157	Brini, M., Nuclear Ca ²⁺ concentration measured with specifically targeted recombinant aequorin. The EMBO Journal vol. 12 no. 12 pp.4813 - 4819, 1993	Bisordi, William		
158	Kalra, E., Nutraceutical - Definition and Introduction. AAPS PharmSci 2003; 5 (3) Article 25	Bisordi, William		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
159	Ahmad, F., Nutraceutical is the Need of Hour. World Journal of Pharmacy and Pharmaceutical Sciences. August 20, 2013. Vol. 2, Issue 5, 2516-2525	Bisordi, William		
160	Lonnerdal, B., Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr 2003;77(suppl):1537S-43S. Biotechnol Lett (2007) 29:1459-1464	Bisordi, William		
161	Pangestuti, R. Optimization of hydrolysis conditions, isolation, and identification of neuroprotective peptides derived from seahorse Hippocampus trimaculatus. Amino Acids (2013) 45: 369-381	Bisordi, William		
162	Grabovac, V. et al., Papain: An Effective Permeation Enhancer for Orally Administered Low Molecular Weight Heparin. Pharmaceutical Research, Vol. 24, No. 5, May 2007 (2007), 1001-06	Bisordi, William		
163	Himaya, S.W. A., Peptide Isolated from Japanese Flounder Skin Gelatin Protects against Cellular Oxidative Damage. J. Agric. Food Chem. 2012, 60, 9112-9119	Bisordi, William		
164	Bannon, G., Protein Digestability and Relevance to Allergenicity. Environmental Health Perspectives. June 2003. 111 (8) 11 22-11 24	Bisordi, William		
165	Beuth, J., Proteolytic Enzyme Therapy in Evidence-Based Complementary Oncology: Fact or Fiction? Integrative Cancer Therapies Vol. 7, No. 4, December 2008. 311-316	Bisordi, William		
166	Fujita, M., Purification and Characterization of a Strong Fibrinolytic Enzyme (Nattokinase) in Vegetable Cheese Natto, a Popular Soybean Fermented Food in Japan. Vol. 197, No. 3, December 30, 1993. 1340-1347	Bisordi, William		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
167	Jae-Young, J. et al., Purification and characterization of an antioxidant peptide obtained from tuna backbone protein by enzymatic hydrolysis. Process Biochemistry 42 (2007) 840- 846	Bisordi, William		
168	Nelson, N., Purple Carrots, Margarine Laced With Wood Pulp? Nutraceuticals Move Into the Supermarket. J Natl Cancer Inst. 1999 May 5;91 (9):755-7	Bisordi, William		
169	Patel, A. et al., Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles. Protein Pept Lett. 2014; 21(11): 1102-1120	Bisordi, William		
170	Muntari, B. et al., Recombinant bromelain production in Escherichia coli: process optimization in shake flask culture by response surface methodology. AMB Express 2012, 2:12	Bisordi, William		
171	Shimomura, O. et al., Resistivity to denaturation of the apoprotein of aequorin and reconstitution of the luminescent photoprotein from the partially denatured apoprotein. Biochem. J. (1981) 199, 825-828	Bisordi, William		
172	Fadl, N. et al., Serrapeptase and nattokinase intervention for relieving Alzheimer's disease pathophysiology in rat model. Human and Experimental Toxicology, 32(7) 721-735 (2013).	Bisordi, William		
173	Bhagat, S. et al., Serratiopeptidase: A systematic review of the existing evidence. International Journal of Surgery 11 (2013) 209-217	Bisordi, William		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
174	Devi, C. et al., Studies on Growth Kinetics of <i>Serratia marcescens</i> VITSD2 and Optimization of Fermentation Conditions for Serratiopeptidase Production. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 2014, 13, 88-92	Bisordi, William		
175	Romano, B. et al., The chemopreventive action of bromelain, from pineapple stem (<i>Ananas comosus</i> L.), on colon carcinogenesis is related to antiproliferative and proapoptotic effects. Mol. Nutr. Food Res. 2013, 00, 1-9	Bisordi, William		
176	Shimomura, O., The discovery of aequorin and green fluorescent protein. Journal of Microscopy, Vol. 217, Pt 1, January 2005, pp. 1-2	Bisordi, William		
177	Lucas, J. S. A., The effect of digestion and pH on the allergenicity of kiwifruit proteins. Pediatr Allergy Immunol 2008; 19: 392-398	Bisordi, William		
178	Latha, B. et al., The efficacy of Trypsin: Chymotrypsin preparation in the reduction of oxidative damage during burn injury. Burns 24 (1998), 532-538	Bisordi, William		
179	Untersmayr. The role of protein digestibility and antacids on food allergy outcomes. J Allergy Clin Immunol. 2008 June. 121(6): 1301-10	Bisordi, William		
180	Starr, R., Too Little, Too Late: Ineffective Regulation of Dietary Supplements in the United States. March 2015, Vol 105, No. 3, American Journal of Public Health	Bisordi, William		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
181	Whitman, M., Understanding the Perceived Need for Complementary and Alternative Nutraceuticals: Lifestyle Issues. CLINICAL JOURNAL OF ONCOLOGY NURSING, VOLUME 5, NUMBER 5, February 2001.01-05	Bisordi, William		
182	Blinks, J., Use of Photoproteins as Intracellular Calcium Indicators. Environmental Health Perspectives, Vol. 84, pp. 75-81, 1990	Bisordi, William		
183	Biziulevicvius, G., Where do the immunostimulatory effects of oral proteolytic enzymes ('systemic enzyme therapy') come from? Microbial proteolysis as a possible starting point. Medical Hypotheses (2006), 67, 1386-1388	Bisordi, William		
184	Bailey, R. et al., Why US Adults Use Dietary Supplements. JAMA INTERN MED. VOL 173 (NO. 5), MAR 11,201, 355-361	Bisordi, William		
185	Fasano, A., Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation , Autoimmunity, and Cancer. Physiol Rev 91: 151-175, 2011	Bisordi, William		
186	Pizzorno, J., Zonulin! The Wheat Conundrum Solved (Well, Mostly ...). Integrative Medicine. August 2013. 12 (4) 8-14	Bisordi, William		
187	Kenna, J.G. et al., Digestibility of proteins in simulated gastric fluid. The Toxicologist. 2000. 54(1). Abstract 666	Goodman, Richard		
188	Bobak, Z. et al., Purification and Characterization of Chicken Pepsinogen and Chicken Pepsin. J Biol Chem. September 10, 1969. 244(17):4638-48.	Goodman, Richard		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
189	Capitan, F. et al., -Lactoglobulin detected in human milk forms noncovalent complexes with maltooligosaccharides as revealed by chip-nanoelectrospray high-resolution tandem mass spectrometry. Amino Acids. November 2015. 47(11): 2399-407.	Goodman, Richard		
190	Buchanan, B.B. et al., Thioredoxin-linked mitigation of allergic responses to wheat. Proc. Natl. Acad. Sci. USA, 1997. 94:5372-5377	Goodman, Richard		
191	Cakir-Kiefer, C. et al., In vitro digestibility of alpha-casozepine, a benzodiazepine-like peptide from bovine casein, and biological activity of its main proteolytic fragment. J. Agric. Food Chem. 2011, 59(9): 4464-4472.	Goodman, Richard		
192	del Val, G. et al., Thioredoxin treatment increases digestibility and lowers allergenicity of milk. J. Allergy Clin. Immunol. 1999. 103:690-697.	Goodman, Richard		
193	Russell, T.L. et al., Upper Gastrointestinal pH in Seventy-Nine Healthy, Elderly, North American Men and Women. Phann. Res. 1993. 10(2): 187-96	Goodman, Richard		
194	Bourlieu, C., et al., Specificity of infant digestive conditions: Some clues for developing relevant in vitro models. Crit. Rev. Food Sci. Nutr. 54(11): 1427-1457.	Goodman, Richard		
195	Okunuki, H. et al., Increased digestibility of two products in genetically modified food (CP4-EPSPS and Cry IAb) after preheating. J. Food Hyg. Soc. Japan. 2002. 43:68-73	Goodman, Richard		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
196	Bernard, H. et al., Peanut allergens are rapidly transferred in human breast milk and can prevent sensitization in mice. Allergy. 2014. 69:888-897	Goodman, Richard		
197	Sen, M. M., Protein structure plays a critical role in peanut allergen stability and may determine immunodominant IgE-binding epitopes. J. Immunol. 2002. 169:882-887	Goodman, Richard		
198	Schlamowitz, M. and Peterson, L.U. Studies on the Optimum pH for the Action of Pepsin on "Native" and Denatured Bovine Serum Albumin and Denatured Bovine Serum Albumin and Bovine Hemoglobin. The Journal of Biological Chemistry. December 1959. 234(12): 3137-45	Goodman, Richard		
199	Fu, T.J. et al., Digestion stability as a criterion for protein allergenicity assessment. Ann. N.Y. Acad. Sci. 2002. 964:99-110.	Goodman, Richard		
200	Picariello, G. et al., Peptides surviving the simulated gastrointestinal digestion of milk proteins: biological and toxicological implications. J. Chromatogr B Analyt. Technol. Biomed. Life Sci. 2010. 878(3-4):295-308	Goodman, Richard		
201	Besler, M. et al., Stability of food allergens and allergenicity of processed foods. J. Chromatogr. B. Biomed. Sci. Appl. 2001. 756(1-2): 207-228.	Goodman, Richard		
202	Tanaka, K., et al., Pepsin-resistant 16 kDa Buckwheat protein is associated with immediate hypersensitivity reactions in patients with Buckwheat allergy. Int. Arch. Allergy Immunol. 2002. 129:49-56	Goodman, Richard		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
203	Thomas, K., et al., A multi-laboratory evaluation of a common in vitro pepsin digestion assay protocol used in assessing the safety of novel proteins. Regul. Toxicol. Pharmacol. 2004. 39:87- 98	Goodman, Richard		
204	Barnett, R. The demonstration with the electron microscope of the end products of histochemical reactions in relation to the fine structure of cells. Exptl. Cell Res. 1959;7:65.	Pezzone, Michael		
205	Dannaeus, A., Inganas, M., Johansson, S.G.O., and Foucard, T. Intestinal uptake of ovalbumin in malabsorption and food allergy in relation to serum IgG antibody and orally administered sodium cromoglycate. Clinical Allergy 1979; 9:263-70	Pezzone, Michael		
206	Husby, S. Normal immune responses to ingested foods. Journal of Pediatric Gastroenterology and Nutrition 2000; 30:s13-19	Pezzone, Michael		
207	Jakobsson, I., Lindberg, T., Lathe, L., Axelson, I., Benediktsson, B. Human B-lactoglobulin as a marker of molecular absorption. Gut 1986 ; 27:1029-34	Pezzone, Michael		
208	Kararli, TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Bipharm Drug Dispos 1995;16:351-80	Pezzone, Michael		
209	Poriadkov, L.F., Kostyleva, M.G., Mazo, V.K, Gmoshinskii, I.V, and Vasilevskaia, L.S. Absorption and the immune response to ovalbumin administration by various methods in the dogs. Voprosy Pitaniia 1986; 6:37-40	Pezzone, Michael		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
210	Ravin, I-I.A, Rowley, D., Jenkins, C., and Fine, J. On the absorption of bacterial endotoxin from the gastrointestinal tract of the normal and shocked animal. J Exptl. Med. 1960;11 2:783	Pezzone, Michael		
211	Sanders, E., and Ashworth, C.T. A study of particulate intestinal absorption and hepatocellular uptake. Use of polystyrene latex particles. Exptl. Cell Res. 1961; 22:137	Pezzone, Michael		
212	Alzheimer's Association, Latest Facts and Figures Report. 2013	Spencer, Brian		
213	Khafagy el, S., et al., Region-Dependent Role of Cell-Penetrating Peptides in Insulin Absorption Across the Rat Small Intestinal Membrane. AAPS J, 2015. 17(6): p. 1427-37	Spencer, Brian		
214	Blennow, K., et al., Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand, 1990. 81(4): p. 323-6	Spencer, Brian		
215	Wallin, A., et al., Blood brain barrier function in vascular dementia. Acta Neurol Scand, 1990. 81(4):p. 318-22	Spencer, Brian		
216	Skrlj, N., et al., Recombinant single-chain antibody with the Trojan peptide penetratin positioned in the linker region enables cargo transfer across the blood-brain barrier. Appl Biochem Biotechnol, 2013. 169(1): p. 159-69	Spencer, Brian		
217	Boado, R.J., et al., Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng, 2007. 97(6): p. 1376- 86	Spencer, Brian		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
218	Prevention, C.f.D.C.a. CDC - Crude and Age-Adjusted Incidence per I,000 Population - Incidence of Diabetes - Date & Trends - Diabetes DDT. 2015; Available from: http://www.cdc.gov/diabetes/statistics/incidence/fig2.htm .	Spencer, Brian		
219	Zlokovic, B.V., et al., Low-density lipoprotein receptor-related protein-I: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta peptide elimination from the brain. J Neurochem, 2010. 115(5): p. 1077-89	Spencer, Brian		
220	Rosenberg, G.A., Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab, 2012. 32(7): p. 1139-51	Spencer, Brian		
221	Petri, B., et al., Chemotherapy of brain tumour using doxorubicin bound to swfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of swfactants. J Control Release, 2007. 117(1): p. 51-8	Spencer, Brian		
222	Kreuter, J., et al., Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target, 2002. 10(4): p. 317-25	Spencer, Brian		
223	Masliyah, E. and B. Spencer, Applications of ApoB LDLR-Binding Domain Approach for the Development of CNS-Penetrating Peptides for Alzheimer's Disease. Methods Mol Biol, 2015. 1324: p. 331-7	Spencer, Brian		
224	Srimanee, A., J. Regberg, and U. Langel, Application of CPPs for Brain Delivery. Methods Mol Biol, 2015. 1324: p. 349-56	Spencer, Brian		

CALL & JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
225	Spencer, B., et al., A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener, 2015. 10(1): p. 48	Spencer, Brian		
226	Spencer, B., et al., ESCRT-mediated uptake and degradation of brain-targeted alpha-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther, 2014. 22(10): p. 1753-67	Spencer, Brian		
227	Zahid, M. and P.D. Robbins, Cell-type specific penetrating peptides: therapeutic promises and challenges. Molecules, 2015. 20(7): p. 13055-70	Spencer, Brian		
228	Minogue, A.M., et al., Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PSI mice. Neurobiol Aging, 2014. 35(6): p. 1442-52	Spencer, Brian		
229	Cimarosti, H. and J.M. Henley, Investigating the mechanisms underlying neuronal death in ischemia using in vitro oxygen-glucose deprivation: potential involvement of protein SUMOylation. Neuroscientist, 2008. 14(6): p. 626-36	Spencer, Brian		
230	Zhang, Y. and D.H. Lee, Sink hypothesis and therapeutic strategies for attenuating Abeta levels. Neuroscientist, 2011. 17(2): p. 163-73	Spencer, Brian		
231	Spencer, B., et al., Peripheral delivery of a CNS targeted, metallo-protease reduces abeta toxicity in a mouse model of Alzheimer's disease. PLoS One, 2011. 6(1): p. el6575	Spencer, Brian		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
232	Stalmans, S., et al., Cell-Penetrating Peptides Selectively Cross the Blood-Brain Barrier In Vivo. PLoS One, 2015. 10(10): p. E0139652	Spencer, Brian		
233	Friden, P.M., et al., Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci US A, 1991. 10 88(11): p. 4771-5	Spencer, Brian		
234	Shin, S.U., et al., Transferrin-antibody fusion proteins are effective in brain targeting. Proceedings of the National Academy of Sciences of the United States of America, 1995. 92(7): p. 2820-4	Spencer, Brian		
235	Spencer, B.J. and I.M. Verma, Targeted delivery of proteins across the blood brain barrier. Proc Natl Acad Sci USA, 2007. 104(18): p. 7594-9	Spencer, Brian		
236	Baker, M.P., et al., Immunogenicity of protein therapeutics: The key causes, consequences and challenges. SelfNonself, 2010. 1(4): p. 314-322	Spencer, Brian		
237	Skoog, I., et al., A population study on blood-brain barrier function in 85-year olds: relation to Alzheimer's disease and vascular dementia. Neurology, 1998. 50(4): p. 966-71	Spencer, Brian		
238	Advertisement: Prevagen Extra Strength Clearer Thinking	Underwood, Mark Moran, Daniel Corporate Representative		
239	Advertisement: Prevagen Extra Strength Clearer Thinking	Underwood, Mark Moran, Daniel Corporate Representative		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
240	Advertisement: Prevagen Brain Cell Protection	Underwood, Mark Moran, Daniel Corporate Representative		
241	Advertisement: Prevagen Clearer Thinking	Underwood, Mark Moran, Daniel Corporate Representative		
242	Advertisement: Prevagen Brain Cell Protection	Underwood, Mark Moran, Daniel Corporate Representative		
243	Advertisement: Prevagen Clearer Thinking	Underwood, Mark Moran, Daniel Corporate Representative		
244	Advertisement: Prevagen Clearer Thinking	Underwood, Mark Moran, Daniel Corporate Representative		
245	Advertisement: Prevagen Clearer Thinking	Underwood, Mark Moran, Daniel Corporate Representative		
246	Advertisement: Prevagen Brain Cell Protection	Underwood, Mark Moran, Daniel Corporate Representative		
247	Advertisement: Prevagen Clearer Thinking	Underwood, Mark Moran, Daniel Corporate Representative		
248	Advertisement: Prevagen Clearer Thinking	Underwood, Mark Moran, Daniel Corporate Representative		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
249	Approval of Prevagen Extra Strength Label	Underwood, Mark Moran, Daniel Corporate Representative		
250	Approval of Prevagen Regular Strength Label and Extra Strength Label	Underwood, Mark Moran, Daniel Corporate Representative		
251	Approval of Prevagen Regular Strength Label	Underwood, Mark Moran, Daniel Corporate Representative		
252	Label: Prevagen	Underwood, Mark Moran, Daniel Corporate Representative		
253	Prevagen Sales	Underwood, Mark Moran, Daniel Corporate Representative		
254	Prevagen Unit Sales	Underwood, Mark Moran, Daniel Corporate Representative		
255	Prevagen Average Prices	Underwood, Mark Moran, Daniel Corporate Representative		
256	Prevagen Sales	Underwood, Mark Moran, Daniel Corporate Representative		
257	This is Your Brain ... And This is Your Brain on Calcium, Vol. 2002, Issue 15, p. ns4	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
258	Biographical Sketch of Mark Underwood	Underwood, Mark Moran, Daniel Corporate Representative		
259	Daniel L. Moran Resume	Underwood, Mark Moran, Daniel Corporate Representative		
260	Letter from Mr. Talati to FDA re New Ingredient Notification for Apoeaquorin	Underwood, Mark Moran, Daniel Corporate Representative		
261	Premarket Notification for New Dietary Ingredient Apoeaquorin	Underwood, Mark Moran, Daniel Corporate Representative		
262	<i>Guevara v. Quincy Bioscience, LLC</i> , et al., BC543851 (Los Angeles Superior Court), Complaint	Underwood, Mark Moran, Daniel Corporate Representative		
263	<i>Hoffman v. Quincy Bioscience, LLC</i> , et al, BER-L-7022-12 (New Jersey Superior Court), Complaint	Underwood, Mark Moran, Daniel Corporate Representative		
264	European Patent Application	Underwood, Mark Moran, Daniel Corporate Representative		
265	Patent Application (2009 Preliminary Amendment) - Appl. No. US2009/036767 Apoeaquorin - Containing Compositions and Methods of Using Same	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
266	Patent Application (2015 supporting documents) - Appl. No. 12 795 955.9	Underwood, Mark Moran, Daniel Corporate Representative		
267	Patent Application (2014) - Appl. No. US2012/065291 Apoaequorin for Reducing Neuronal Injury Due to Ischemia	Underwood, Mark Moran, Daniel Corporate Representative		
268	Patent Application (2013 Amendment) - Appl. No. US2013/062268 Methods for Alleviating Symptoms of Multiple Sclerosis Based on Apoaequorin-Containing Compositions	Underwood, Mark Moran, Daniel Corporate Representative		
269	Patent Application (2016 Amendment) Method of Treating Ischemic Injury Using Apoaequorin	Underwood, Mark Moran, Daniel Corporate Representative		
270	Patent Application (2004) - Appl. No. 10/872,795 Aequorin-Containing Compositions and Methods of Using Same	Underwood, Mark Moran, Daniel Corporate Representative		
271	Patent Application (2006) - Appl. No. 11/571043 Aequorin-Containing Compositions and Methods of Using Same	Underwood, Mark Moran, Daniel Corporate Representative		
272	Patent Application (2010) - Appl. No. 12/694427 Aequorin-Containing Compositions and Methods of Using Same	Underwood, Mark Moran, Daniel Corporate Representative		
273	Patent Application (2018) - Appl. No. US2015/060116 Apoaequorin-Containing Compositions and Methods of Using Same to Treat Neuronal Inflammation	Underwood, Mark Moran, Daniel Corporate Representative		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
274	Letter from Ashish Talati to FDA Re: Quincy Bioscience Manufacturing, Inc., Warning Letter MIN 13-03	Underwood, Mark Moran, Daniel Corporate Representative		
275	Letter from FDA to Dr. Moran	Underwood, Mark Moran, Daniel Corporate Representative		
276	Letter from Ashish Talati to FDA Re: Apoeaquorin Dietary Ingredient Safety	Underwood, Mark Moran, Daniel Corporate Representative		
277	Letter from Ashish Talati to FDA Re: Quincy Bioscience Manufacturing, Inc., Apoeaquorin Dietary Ingredient	Underwood, Mark Moran, Daniel Corporate Representative		
278	Letter from FDA to Mr. Talati	Underwood, Mark Moran, Daniel Corporate Representative		
279	Letter from Quincy to FDA Re: Quincy Bioscience Manufacturing, Inc., Warning Letter MIN 13-03	Underwood, Mark Moran, Daniel Corporate Representative		
280	Letter from Quincy to FDA Re: Quincy Bioscience Manufacturing, Inc. Response to Warning Letter MIN 13-03, Items 1.4, 3.2.1, 4.1 and 4.4	Underwood, Mark Moran, Daniel Corporate Representative		
281	Advertisement: Did you know the active ingredient in Prevagen won the Nobel Prize?	Underwood, Mark Moran, Daniel Corporate Representative		
282	Advertisement: No Fooling. Prevagen Improves Memory	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
283	Advertisement: Did you know Prevagen is proven to help you remember driving directions?	Underwood, Mark Moran, Daniel Corporate Representative		
284	Advertisement: Did you know Prevagen is proven to help you retain information?	Underwood, Mark Moran, Daniel Corporate Representative		
285	Advertisement: Within 60 days, 63% said they were feeling less forgetful	Underwood, Mark Moran, Daniel Corporate Representative		
286	Advertisement: Did you know Prevagen is proven to help you feel less forgetful?	Underwood, Mark Moran, Daniel Corporate Representative		
287	Advertisement: A benefit of a better brain is having confidence to try new things.	Underwood, Mark Moran, Daniel Corporate Representative		
288	Advertisement: Enjoy life more from an elevated mood.	Underwood, Mark Moran, Daniel Corporate Representative		
289	Advertisement: A benefit of better brain health is more uninterrupted sleep.	Underwood, Mark Moran, Daniel Corporate Representative		
290	Advertisement: A benefit of a better brain is enhanced decision-making skills!	Underwood, Mark Moran, Daniel Corporate Representative		
291	Advertisement: Issue #2 - Protective Proteins in the Brain	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
292	Advertisement: The Proven Secret to a Better Memory (Bottom Line Health Enewsletter)	Underwood, Mark Moran, Daniel Corporate Representative		
293	Advertisement: The Proven Secret to a Better Memory (Lake Group Media Health Enewsletter)	Underwood, Mark Moran, Daniel Corporate Representative		
294	Advertisement: Did you know the active ingredient in Prevagen won the Nobel Prize? (Newsmax Enewsletter)	Underwood, Mark Moran, Daniel Corporate Representative		
295	Advertisement: Issue #2 - Protective Proteins in the Brain	Underwood, Mark Moran, Daniel Corporate Representative		
296	Advertisement: Issue #5 - The Substantiation for Long-Term Benefits	Underwood, Mark Moran, Daniel Corporate Representative		
297	Press Release: Better Memory Tour Reaches Philadelphia	Underwood, Mark Moran, Daniel Corporate Representative		
298	Press Release: Brain Booster Supplement Manufacturer Recommends Prevagen for Safer Driving	Underwood, Mark Moran, Daniel Corporate Representative		
299	Press Release: Prevagen Announce prevagenreviews.com	Underwood, Mark Moran, Daniel Corporate Representative		
300	Press Release: Quincy Bioscience Announces Publication of Brian Health Guide Second Edition	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
301	Press Release: Quincy Bioscience Announces Free Tool to Reduce Holiday Stress	Underwood, Mark Moran, Daniel Corporate Representative		
302	Press Release: Quincy Bioscience Celebrates 5th Birthday of Prevagen	Underwood, Mark Moran, Daniel Corporate Representative		
303	Press Release: Quincy Bioscience Makes Inc. 500 List of America's Fastest Growing Companies	Underwood, Mark Moran, Daniel Corporate Representative		
304	Press Release: The Brain Health Guide Give Away...In Recognition of Brain Awareness Week	Underwood, Mark Moran, Daniel Corporate Representative		
305	Press Release: Quincy Bioscience Obtains Self-Affirmed GRAS Status for its Apoeaquorin Ingredient	Underwood, Mark Moran, Daniel Corporate Representative		
306	Press Release: Prevagen Reaches Full Distribution in CVS Stores Nationwide	Underwood, Mark Moran, Daniel Corporate Representative		
307	Press Release: Quincy Bioscience Launches New National Advertisement in USA Today	Underwood, Mark Moran, Daniel Corporate Representative		
308	Press Release: Quincy Bioscience Announces the Kickoff of the Prevagen Blog	Underwood, Mark Moran, Daniel Corporate Representative		
309	Press Release: Prevagen Extra Strength Now Available Online	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
310	Press Release: Prevagen Now Available Nationwide at Vitamin Shoppe	Underwood, Mark Moran, Daniel Corporate Representative		
311	Press Release: Quincy Bioscience Announce the Launch of NeuroShake	Underwood, Mark Moran, Daniel Corporate Representative		
312	Press Release: Safety Assessment Study of Apoeaquorin Published in Food and Chemical Toxicology	Underwood, Mark Moran, Daniel Corporate Representative		
313	Press Release: Brain Health Videos by Quincy Bioscience Available on YouTube	Underwood, Mark Moran, Daniel Corporate Representative		
314	Press Release: Quincy Bioscience Launches Prevagen FAQ Video Series	Underwood, Mark Moran, Daniel Corporate Representative		
315	Press Release: Quincy Bioscience Launches the Fourth Edition of the Brain Health Guide	Underwood, Mark Moran, Daniel Corporate Representative		
316	Press Release: Safety Assessment of Apoeaquorin Published in Regulatory Toxicology and Pharmacology	Underwood, Mark Moran, Daniel Corporate Representative		
317	Press Release: Prevagen Brain Health Supplement Reaches Distribution in Meijer Stores Nationwide	Underwood, Mark Moran, Daniel Corporate Representative		
318	Advertisement: Save 10% Off Prevagen Site Wide	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
319	Letter/Advertisement from Dakota Miller	Underwood, Mark Moran, Daniel Corporate Representative		
320	Letter/Advertisement from Dakota Miller	Underwood, Mark Moran, Daniel Corporate Representative		
321	Letter/Advertisement from Mark Underwood	Underwood, Mark Moran, Daniel Corporate Representative		
322	Advertisement: Can a protein originally found in a jellyfish improve your memory?	Underwood, Mark Moran, Daniel Corporate Representative		
323	Health Today - The Simple Way to Better Brain Health	Underwood, Mark Moran, Daniel Corporate Representative		
324	Advertisement: The New Secrets of Brain Health	Underwood, Mark Moran, Daniel Corporate Representative		
325	Advertisement: Can a protein originally found in a jellyfish improve your memory?	Underwood, Mark Moran, Daniel Corporate Representative		
326	Advertisement: Can a protein originally found in a jellyfish improve your memory?	Underwood, Mark Moran, Daniel Corporate Representative		
327	Advertisement: Can a protein originally found in a jellyfish improve your memory?	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
328	Advertisement: Can a protein from jellyfish give you a better memory?	Underwood, Mark Moran, Daniel Corporate Representative		
329	Advertisement: Can a protein originally found in a jellyfish improve your memory?	Underwood, Mark Moran, Daniel Corporate Representative		
330	Advertisement: Can a protein from jellyfish give you a better memory?	Underwood, Mark Moran, Daniel Corporate Representative		
331	Advertisement: Prevagen	Underwood, Mark Moran, Daniel Corporate Representative		
332	Advertisement: Prevagen	Underwood, Mark Moran, Daniel Corporate Representative		
333	Advertisement: Sign up and join us fo the Better Memory Tour!	Underwood, Mark Moran, Daniel Corporate Representative		
334	Advertisement: Feeling Foggy?	Underwood, Mark Moran, Daniel Corporate Representative		
335	Advertisement: First Bottle Free	Underwood, Mark Moran, Daniel Corporate Representative		
336	Advertisement: The Effects of Prevagen on Memory	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
337	Advertisement: Free Memory Screening On-Site Event at Your Store!	Underwood, Mark Moran, Daniel Corporate Representative		
338	Advertisement: New National Medi Campaign	Underwood, Mark Moran, Daniel Corporate Representative		
339	Advertisement: We are driving trafice to your pharmacy	Underwood, Mark Moran, Daniel Corporate Representative		
340	First Amended Class Action Complaint			
341	Advertisement: The New Secrets of Brain Health	Underwood, Mark Moran, Daniel Corporate Representative		
342	Advertisement: Sign up for our free live presentation "The New Secrets of Brain Health"	Underwood, Mark Moran, Daniel Corporate Representative		
343	Advertisement: Your favorite memory supplement now in a delicious chewable!	Underwood, Mark Moran, Daniel Corporate Representative		
344	Advertisement: Could your memory use a boost?	Underwood, Mark Moran, Daniel Corporate Representative		
345	Advertisement: Improve your memory within 90 days	Underwood, Mark Moran, Daniel Corporate Representative		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
346	The Brain Health Guide: 2nd Edition (notice)	Underwood, Mark Moran, Daniel Corporate Representative		
347	Presentation: Prevagen Professional Improves Memory	Underwood, Mark Moran, Daniel Corporate Representative		
348	Advertisement: Prevagen Professional Helps Memory (Natural Partners)	Underwood, Mark Moran, Daniel Corporate Representative		
349	Prevagen Pricing	Underwood, Mark Moran, Daniel Corporate Representative		
350	Sharpen Your Mind	Underwood, Mark Moran, Daniel Corporate Representative		
351	Transcript: 60 second commercial to promote speaking engagement in The Villages	Underwood, Mark Moran, Daniel Corporate Representative		
352	Sales Script	Underwood, Mark Moran, Daniel Corporate Representative		
353	Sales Script	Underwood, Mark Moran, Daniel Corporate Representative		
354	Sales Script: Objections	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
355	Presentation: Prevagen Improves Memory	Underwood, Mark Moran, Daniel Corporate Representative		
356	Ingredient List	Underwood, Mark Moran, Daniel Corporate Representative		
357	Labeling Statements	Underwood, Mark Moran, Daniel Corporate Representative		
358	Draft Memo re Store Product Placement	Underwood, Mark Moran, Daniel Corporate Representative		
359	Sales Script - Verbatim Document	Underwood, Mark Moran, Daniel Corporate Representative		
360	Sales Script - Verbatim Document	Underwood, Mark Moran, Daniel Corporate Representative		
361	Sales Script - Verbatim Document	Underwood, Mark Moran, Daniel Corporate Representative		
362	Transcript: Infomerical Content (Teri Barr, Mark Underwood)	Underwood, Mark Moran, Daniel Corporate Representative		
363	Transcript: Infomerical Content (Teri Barr, Mark Underwood) (EDITS)	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
364	Transcript: Infomerical Content (Teri Barr, Mark Underwood) (EDITS)	Underwood, Mark Moran, Daniel Corporate Representative		
365	Transcript: Prevagen advertising transcript (7230)	Underwood, Mark Moran, Daniel Corporate Representative		
366	Transcript: Prevagen advertising transcript - "Please do not air this show any longer!!!" (7233)	Underwood, Mark Moran, Daniel Corporate Representative		
367	Transcript: Prevagen advertising transcript (7402)	Underwood, Mark Moran, Daniel Corporate Representative		
368	Transcript: Prevagen advertising transcript (7550)	Underwood, Mark Moran, Daniel Corporate Representative		
369	Transcript: Prevagen advertising transcript (7551)	Underwood, Mark Moran, Daniel Corporate Representative		
370	Transcript: Prevagen advertising transcript (7728)	Underwood, Mark Moran, Daniel Corporate Representative		
371	Transcript: Prevagen Advertising script noting "Please do not air this show any longer!!!" (8200)	Underwood, Mark Moran, Daniel Corporate Representative		
372	Transcript: Prevagen Advertising script (8201)	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
373	Transcript: Prevagen Advertising script noting "Please do not air this show any longer!!" (8202)	Underwood, Mark Moran, Daniel Corporate Representative		
374	Transcript: Prevagen Advertising script noting "Please do not air this show any longer!!" (8203)	Underwood, Mark Moran, Daniel Corporate Representative		
375	Transcript: Prevagen Advertising script noting "Please do not air this show any longer!!" (8403)	Underwood, Mark Moran, Daniel Corporate Representative		
376	Testimonial Questions	Underwood, Mark Moran, Daniel Corporate Representative		
377	Email: Prevagen From: Tom Dvorak To: Mark Underwood	Underwood, Mark Moran, Daniel Corporate Representative		
378	Email: Prevagen From: Tom Dvorak To: Mark Underwood	Underwood, Mark Moran, Daniel Corporate Representative		
379	Impact of Prevagen on Memory - Prevagen Quality of Life Study	Underwood, Mark Moran, Daniel Corporate Representative		
380	Sponsored Research Agreement	Underwood, Mark Moran, Daniel Corporate Representative		
381	Email: Memory study participants finished at end of Dec From: Peggy Sivescind To: Todd Olson, Mark Underwood, Taylor Gabourie, Kenneth Lerner	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
382	Advertisement: Participate in a "Quality of Life" Study	Underwood, Mark Moran, Daniel Corporate Representative		
383	Email: placebo trial assignment.xls From: Mark Underwood To: Josh Jackson	Underwood, Mark Moran, Daniel Corporate Representative		
384	CV of Peggy A. Sivesind	Underwood, Mark Moran, Daniel Corporate Representative		
385	The Effects of the Calcium Binding Protein Apoaequorin on Memory and Cognitive Functioning in Older Adults	Underwood, Mark Moran, Daniel Corporate Representative		
386	Advertisement: Prevagen Clearer Thinking	Underwood, Mark Moran, Daniel Corporate Representative		
387	Email: percentage improved? From: Todd Olson To: Mark Underwood	Underwood, Mark Moran, Daniel Corporate Representative		
388	Email: MMS Canada Edits From: Mark Underwood To: Mike Moran, Kenneth Lerner, Todd Olson	Underwood, Mark Moran, Daniel Corporate Representative		
389	Email: MMS Write Up 4 March 14.2.docx From: Mark Underwood To: Kenneth Lerner, Todd Olson	Underwood, Mark Moran, Daniel Corporate Representative		
390	Discussion of Madison Memory Study	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
391	Effect of an Apoaequorin Containing Supplement on Verbal Learning in Community Dwelling, Older Adults	Underwood, Mark Moran, Daniel Corporate Representative		
392	Madison Memory and Executive Function Write Up (draft)	Underwood, Mark Moran, Daniel Corporate Representative		
393	Effect of an Apoaequorin Containing Supplement on Verbal Learning in Community Dwelling, Older Adults	Underwood, Mark Moran, Daniel Corporate Representative		
394	2011 Statement from Quincy Bioscience regarding AQ	Underwood, Mark Moran, Daniel Corporate Representative		
395	Quincy Bioscience Reports Encouraging Preliminary Data from Memory Study	Underwood, Mark Moran, Daniel Corporate Representative		
396	Prevagen Improves Memory in 30 days (2008 Memory Study)	Underwood, Mark Moran, Daniel Corporate Representative		
397	Email: Madison Memory Study Percent Change From: Taylor Gabourie To: Mark Underwood, Kenneth Lerner	Underwood, Mark Moran, Daniel Corporate Representative		
398	Email: Prevagen Quality of Life Survey From: Taylor Gabourie To: Mark Underwood	Underwood, Mark Moran, Daniel Corporate Representative		
399	Fibromyalgia study summary	Underwood, Mark Moran, Daniel Corporate Representative		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
400	Prevagen Fibromyalgia Study Talking Points	Underwood, Mark Moran, Daniel Corporate Representative		
401	Prevagen Professional Fibromyalgia/Chronic Fatigue Study	Underwood, Mark Moran, Daniel Corporate Representative		
402	MS HOPE TRIAL - Statistical Analysis Including Graphical Representation	Underwood, Mark Moran, Daniel Corporate Representative		
403	Relapsing and Remission Analysis: MS HOPE & MS Continuation Trials	Underwood, Mark Moran, Daniel Corporate Representative		
404	Madison Memory Study (1st version)	Underwood, Mark Moran, Daniel Corporate Representative		
405	Madison Memory Study (protocol)	Underwood, Mark Moran, Daniel Corporate Representative		
406	Monitoring test results for "Prevagen" which contains apoeaquorin (R&D Division, Development Section - Sunsho Pharmaceutical Company Limited)	Underwood, Mark Moran, Daniel Corporate Representative		
407	Premarket Notification for New Dietary Ingredient Apoeaquorin	Underwood, Mark Moran, Daniel Corporate Representative		
408	Letter from Mark Underwood to FDA re: Quincy Bioscience Manufacturing, Inc. - Warning Letter MIN 13-03	Underwood, Mark Moran, Daniel Corporate Representative		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
409	Email: Quincy Bioscience From: Ashish Talati To: Louisa Nickerson	Underwood, Mark Moran, Daniel Corporate Representative		
410	Letter from FDA re receiving response to Warning Letter MIN 13-03	Underwood, Mark Moran, Daniel Corporate Representative		
411	Letter from FDA re Warning Letter MIN 13-03	Underwood, Mark Moran, Daniel Corporate Representative		
412	Letter to Quincy Bioscience from County of Santa Cruz District Attorney's Office Re: Demand to Substantiate Claims Made Concerning the products Prevagen, Prevagen Extra Strength, Prevagen Professional and Prevagen Chewables	Underwood, Mark Moran, Daniel Corporate Representative		
413	Letter from Quincy responding to Santa Cruz District Attorney's Office	Underwood, Mark Moran, Daniel Corporate Representative		
414	Quincy Bioscience, LLC Substantiation Overview	Underwood, Mark Moran, Daniel Corporate Representative		
415	Exhibits submitted to Santa Cruz District Attorney's Office	Underwood, Mark Moran, Daniel Corporate Representative		
416	Bojsen-Moller KN, Jacobsen SH, Dirksen C, et al. Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. The American journal of clinical nutrition 2015;102:600-7.	Bazinet, Richard		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
417	Bromelain (Medline Plus)	Bisordi, William		
418	Chen, C., Ma, D., Kim, J., Mount, H., Bazinet, R. The low density lipoprotein receptor is not necessary for maintaining mouse brain polysaturated fatty acid concentrations, Journal of Lipid Research, 49 (2008)	Bazinet, Richard		
419	ExPASy PeptideCutter Exhibit	Goodman, Richard		
420	Foltz M, van der Pijl PC, Duchateau GS. Current in vitro testing of bioactive peptides is not valuable. J Nutr 2010;140:117-8.	Bazinet, Richard		
421	Fouz, N., Gene Expression Analysis in MCF-7 Breast Cancer Cells Treated with Recombinant Bromelain. Appl Biochem Biotechnol (2014) 173:1618-1639	Bisordi, William		
422	Gardner ML. Intestinal Assimilation of Intact Peptides and Proteins from the Diet - a Neglected Field? Biol. Rev. (1984) 59, pp.289-331	Bisordi, William		
423	Gupta, S., Oral delivery of therapeutic proteins and peptides: a review on recent developments	Bisordi, William		
424	Heyman, M., Boudraa, G., Sarrut, S., Giraud, M., Evans, L., Touhami, M., Desjeux, J.F. Macromolecular transport in jejuna mucosa of children with severe malnutrition: a quantitative study. J Pediatr Gastroenterol Nut 1984; 3:357-363	Pezzone, Michael		
425	Husby S, Jensenius JC, Svehag SE. Passage of undegraded dietary antigen into the blood of healthy adults. Scand J Immunol 1985c;22:83-92	Pezzone, Michael		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
426	Husby, S., Jensenius, S.C., Svehag, S.E. Passage of undegraded dietary antigen in the blood of healthy adults. Further characterization of the kinetics of uptake and the size of distribution of the antigen. Scan J Immunol 1986; 24:447-455	Pezzone, Michael		
427	Jamnik J, Garcia-Bailo B, Borchers CH, El-Sohehy A. Gluten Intake Is Positively Associated with Plasma alpha2-Macroglobulin in Young Adults. The Journal of nutrition 2015;145:1256-62.	Bazinet, Richard		
428	Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Molecular & cellular proteomic : MCP 2007;6:2212-29.	Bazinet, Richard		
429	Luttikhoud J, van Norren K, Buijs N, et al. Jejunal Casein Feeding Is Followed by More Rapid Protein Digestion and Amino Acid Absorption When Compared with Gastric Feeding in Healthy Young Men. The Journal of nutrition 2015;145:2033-8.	Bazinet, Richard		
430	Mains RE, Eipper BA. The Neuropeptides: Philadelphia: Lippincott-Raven; 1999.	Bazinet, Richard		
431	Miner-Williams, Warren, Are intact peptides absorbed from the healthy gut in the adult human?, Nutr. Research Reviews (2014) 27, 308-329	Bisordi, William		
432	Neuroscience & Public Policy Dual-Degree Program (University of Wisconsin - Madison) - "Jellyfish protein improves memory?"	Spencer, Brian		
433	Oishi, O., Validity of putative calcium binding loops of photoprotein aequorin. FEBS Lett. 1992 Aug 3;307(3):272-4	Bisordi, William		

CALL &
JENSEN
EST. 1981

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
434	Parlesak, A., Schafer, C., Schutz, T., Bode, J.C., and Bode, C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J. Hepatology 2000; 32:742-47	Pezzone, Michael		
435	Parrott, M., Winocur, G., Bazinet, R., Ma, D., Greenwood, C., Whole-food diet worsened cognitive dysfunction in an Alzheimer's disease mouse model, Neurobiology of Aging 36 (2015) 90-99	Bazinet, Richard		
436	Picariello, G. et al., Protein digestomics: Integrative platforms to study food-protein digestion and derived functional and active peptides. Trends Anal. Chem. 2013. 52:120-134	Goodman, Richard		
437	Rao, J., Ertley, R., Rapoport, S., Bazinet, R., Lee, H., Chronic NMDA administration to rats up-regulates frontal cortex cystolic phospholipase A2 and its transcription factor, activator protein-2, Journal of Neurochemistry, 2007 102, 1918-1927	Bazinet, Richard		
438	Regenthal R, Krueger M, Koeppel C, Preiss R. Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput 1999;15:529-44.	Bazinet, Richard		
439	Schatten, W.E. The role of intestinal bacteria in liver necrosis following experimental excision of the hepatic arterial supply. Surgery 1954; 36:256	Pezzone, Michael		
440	Spencer, B. and Masliah, E., Immunotherapy for Alzheimer's disease: past, present and future. Frontiers in Aging Neuroscience, 10 June 2014	Spencer, Brian		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
441	Spencer, B. CNS targeted peptides and proteins for the treatment of neurological disorders, International Conference on Genetic Syndromes & Gene Therapy	Spencer, Brian		
442	Spencer, B., et al., Peripheral delivery of a CNS targeted, metallo-protease reduces abeta toxicity in a mouse model of Alzheimer's disease. PLoS One, 2011. 6(1): p. el6575	Spencer, Brian		
443	Spencer, B.J. and I.M. Verma, Targeted delivery of proteins across the blood brain barrier. Proc Natl Acad Sci US A, 2007. 104(18): p. 7594-9 - with notes	Spencer, Brian		
444	Tanaka Y, Akiyama H, Kuroda T, et al. A novel approach and protocol for discovering extremely low-abundance proteins in serum. Proteomics 2006;6:4845-55.	Bazinet, Richard		
445	Targeting polypeptides to the central nervous system, Patent WO 2004108071 A2	Spencer, Brian		
446	Transcript: Radio Show (Chris McKay and Mark Underwood)	Underwood, Mark Moran, Daniel Corporate Representative		
447	UCSD Experimental Neuropath Laboratory - Faculty & Staff	Spencer, Brian		
448	Unzeitig, V., Systemic Enzyme Therapy Treatment of Recurrent Vulvovaginal Candidiasis. Ces. Gynek.2013, 78, c. 2 s. 187-194 (abstract)	Bisordi, William		
449	WSJ Article: Jeffrey Johnson and Ronald Kalil: No reason to buy into brain chain	Spencer, Brian		
450	Yin, L., Bioproperties of Potent Nattokinase from Bacillus subtilis YJI. J. Agric. Food Chem. 2010, 58, 5737- 5742	Bisordi, William		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
451	Email Chain with Defense regarding damages spreadsheets	Underwood, Mark Moran, Daniel Corporate Representative		
452	Defendant's Supplemental Responses to Interrogatories, Nos 19-25 (sales)	Underwood, Mark Moran, Daniel Corporate Representative		
453	Defendant's Supplemental Responses to RFA, Set Two	Underwood, Mark Moran, Daniel Corporate Representative		
454	<i>FTC v. Quincy Bioscience Holding Co., et al</i> , Case No. 17:cv-00124-LLS (S.D. N.Y.)	Underwood, Mark Moran, Daniel Corporate Representative		
455	<i>FTC v. Quincy Bioscience Holding Co., et al</i> , Case No. 17:cv-00124-LLS (S.D. N.Y.), Exhibit A (Label)	Underwood, Mark Moran, Daniel Corporate Representative		
456	<i>FTC v. Quincy Bioscience Holding Co., et al</i> , Case No. 17:cv-00124-LLS (S.D. N.Y.), Exhibit B-1 (FTC Transcript dated February 22, 2016)	Underwood, Mark Moran, Daniel Corporate Representative		
457	<i>FTC v. Quincy Bioscience Holding Co., et al</i> , Case No. 17:cv-00124-LLS (S.D. N.Y.), Exhibit C (Prevagen Website)	Underwood, Mark Moran, Daniel Corporate Representative		
458	<i>FTC v. Quincy Bioscience Holding Co., et al</i> , Case No. 17:cv-00124-LLS (S.D. N.Y.), Exhibit D (Brain Health Guide, 4th Ed. 2014)	Underwood, Mark Moran, Daniel Corporate Representative		
459	<i>FTC v. Quincy Bioscience Holding Co., et al</i> , Case No. 17:cv-00124-LLS (S.D. N.Y.), Exhibit E-1 (FTC Transcript dated March 20, 2016)	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
460	<i>FTC v. Quincy Bioscience Holding Co., et al</i> , Case No. 17:cv-00124-LLS (S.D. N.Y.), Exhibit F (Prevagen Bus)	Underwood, Mark Moran, Daniel Corporate Representative		
461	<i>Collins v. Quincy Bioscience, LLC</i> , Case No. 19-cv-22864-MGC (S.D. Fla.), Declaration of Keith Thomsen in Support of Defendant's Memorandum of Law in Opposition to Plaintiffs' Motion for Class Certification with supporting Exhibits: Ex. A (screenshots of Prevagen FAQs on website); Ex. B (screenshots of Prevagen products and retail prices on website)	Underwood, Mark Moran, Daniel Corporate Representative		
462	<i>Collins v. Quincy Bioscience, LLC</i> , Case No. 19-cv-22864-MGC (S.D. Fla.), Declaration of Glenn T. Graham in Support of Defendant's Memorandum of Law in Opposition to Plaintiffs' Motion for Class Certification (without exhibits)	Underwood, Mark Moran, Daniel Corporate Representative		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
463	<i>Collins v. Quincy Bioscience, LLC</i> , Case No. 19-cv-22864-MGC (S.D. Fla.), Declaration of Todd Olson in Support of Defendant's Memorandum of Law in Opposition to Plaintiffs' Motion for Class Certification with supporting Exhibits: Ex. A (examples of Prevagen Product labels and packaging materials bearing the product descriptor "Jellyfish Fight Aging"); Ex. B (examples of the Prevagen Product labels and packaging materials bearing the product descriptor "Brain Cell Protection"); Ex. C (examples of the Prevagen Product labels and packaging material bearing the product descriptor "Clearer Thinking"); Ex. D (examples of the Prevagen Product labels and packaging material bearing the product descriptor "Improves Memory"); Ex. E (examples of the Prevagen Product labels reflecting the addition of Vitamin D3); Ex. F (Brain Cell Protection Package Insert); Ex. G (Clearer Thinking Package Insert); and Ex. H (Improves Memory Package Insert)	Underwood, Mark Moran, Daniel Corporate Representative		
464	Expert Report of Richard P. Bazinet, Ph.D.	Bazinet, Richard		
465	Rebuttal Report of Expert Richard P. Bazinet	Bazinet, Richard		
466	Expert Report of Michael A. Pezzone, M.D., Ph.D.	Pezzone, Michael		
467	Expert Report of Richard E. Goodman, Ph.D.	Goodman, Richard		
468	Expert Report of Brian Spencer, Ph.D.	Spencer, Brian		
469	Expert Report of William Bisordi, M.D., F.A.C.P.	Bisordi, William		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
470	Osamu Shimomura (Wikipedia page)	Underwood, Mark		
471	Quincy Bioscience Website (screenshots)	Underwood, Mark Moran, Daniel Corporate Representative		
472	Prevagen website (screenshots)	Underwood, Mark Moran, Daniel Corporate Representative		
473	Email chain with defense regarding sales numbers from 2017 to May 2019	Underwood, Mark Moran, Daniel Corporate Representative		
474	PAK Technologies (screen shots of website)	Underwood, Mark		
475	LinkedIn re Quincy	Underwood, Mark Moran, Daniel Corporate Representative		
476	LinkedIn re Underwood	Underwood, Mark		
477	LinkedIn re Moran	Moran, Daniel		
478	Defendant's Answer to First Amended Complaint	Underwood, Mark Moran, Daniel Corporate Representative		
479	Declaration of Dr. Richard Bazinet	Bazinet, Richard		
480	Declaration of Mark Y. Underwood in Support of Defendant's Opposition to Motion for Class Certification	Underwood, Mark		
481	Declaration of Mark Y. Underwood in Support of Plaintiff's Administrative Motion to File Documents Under Seal	Underwood, Mark		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
482	Defendant's Responses to Plaintiff's Request for Production of Documents, Set One	Underwood, Mark Moran, Daniel Corporate Representative		
483	Defendant's Responses to Plaintiff's Request for Admissions, Set One	Underwood, Mark Moran, Daniel Corporate Representative		
484	Defendant's Responses to Interrogatories, Set One	Underwood, Mark Moran, Daniel Corporate Representative		
485	Defendant's Responses to Plaintiff's Request for Production of Documents, Set Two	Underwood, Mark Moran, Daniel Corporate Representative		
486	Defendant's Responses to Plaintiff's Request for Admissions, Set Two	Underwood, Mark Moran, Daniel Corporate Representative		
487	Defendant's Responses to Interrogatories, Set Two	Underwood, Mark Moran, Daniel Corporate Representative		
488	Defendant's Supplemental Responses to Request for Production of Documents, Set Two	Underwood, Mark Moran, Daniel Corporate Representative		
489	Fu, T.J., Digestibility of Food Allergens and Nonallergenic Proteins in Simulated Gastric Fluid and Simulated Intestinal Fluids A Comparative Study. J. Agric. Food Chem. 2002, 50, 7154-7160.	Bisordi, William		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
490	Fu, T.J. et al., Digestibility of food allergens and non-allergenic proteins in simulated gastric and intestinal fluids-a comparative study. J. Agric. Food Chem. 2002. 50:7154-7160.	Goodman, Richard E.		
491	Adams, Erin L., SfN Abstract 2015 - Oral Administration of AQ is neuroprotective in an acute slice model of oxygen-glucose deprivation;	Underwood, Mark		
492	Ehlers, Vanessa L., et al., SfN Abstract 2015 – Effects of the calcium-binding protein apoequorin on acquisition of trace fear conditioning in adult and aging rats;	Underwood, Mark		
493	Aequorin injected prior to ischemia is neuroprotective;	Underwood, Mark		
494	Detert, Julia A., Aequorin Protects Adult and Aging Hippocampal CA1 Neurons from Ischemic Cell Death;	Underwood, Mark		
495	Hochstetter1, Erin L., Apoequorin protects neurons from ischemia and alters cytokine mRNA levels in rat hippocampus;	Underwood, Mark		
496	Carafoli, Ernesto, Calcium Signaling: A tale for all seasons, PNAS, February 5, 2002 vol. 99, No. 3, 1115-1122;	Underwood, Mark		
497	Mattson, Mark P., Calcium Neurodegeneration, Aging Cell (2007) Vol. 6 pp.337–350;	Underwood, Mark		
498	Baimbridge, K.G., et. al., Calcium-binding proteins in the nervous system, TINS, Vol. 15, No. 8, 1992;	Underwood, Mark		
499	UWM Poster;	Underwood, Mark		
500	UWM Poster;	Underwood, Mark		
501	UWM Poster;	Underwood, Mark		
502	UWM Poster;	Underwood, Mark		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
503	UWM Poster;	Underwood, Mark		
504	UWM Poster;	Underwood, Mark		
505	Detert, Julia A., et. al, Pretreatment with Apoequorin Protects Hippocampal CA1 Neurons from Oxygen-Glucose Deprivation;	Underwood, Mark		
506	Detert, J.A., Evaluation of aging-related changes in calcium binding proteins in rat medial prefrontal cortex;	Underwood, Mark		
507	Milgram, Norton William PhD, et al., Enhancement of Cognitive Function in Aged Canines with Apoequorin, a Calcium Binding Protein;	Underwood, Mark		
508	Detert, J.A., et al., Neuroprotective effect of aequorin on hippocampal CA1 neurons following ischemia, Neuroscience 2006, Oasis the Online Abstract Submission System;	Underwood, Mark		
509	Society For Neuroscience Presentation Certificates;	Underwood, Mark		
510	Adams, E., Orally administered apoequorin protects neurons from oxygen-glucose deprivation; (Spencer Depo. Exhibit 12)	Underwood, Mark		
511	Effect of Apoequorin on Discrimination Learning and Selective Attention in Aged Beagle Dogs;	Underwood, Mark		
512	Leslie, Mitch, This Is Your Brain . . . And This Is Your Brain on Calcium, Vol. 2002, Issue 15, p. ns4;	Underwood, Mark		
513	Toescu, Emil C., et. al., The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging, Aging Cell (2007) 6. Pp. 267-273;	Underwood, Mark		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
514	Detert, Julia A., Time Course and Effectiveness of Apoaeqorin as a Neuroprotectant in the Brain, University of Wisconsin-Milwaukee, Milwaukee, WI 53201;	Underwood, Mark		
515	Artwork for Labels;	Underwood, Mark		
516	Quarterly Financials for CA (needs redaction of other states);	Underwood, Mark		
517	Written Testimonials;	Underwood, Mark		
518	Recorded Testimonials;	Underwood, Mark		
519	Withdrawn			
520	Notice of Taking Deposition Duces Tecum of Richard P. Bazinet; (Bazinet Depo. Exhibit 2)	Bazinet, Richard P.		
521	Bazinet Depo. Exhibit 3	Underwood, Mark		
522	Invoices; (Bazinet Depo. Exhibit 12)	Bazinet, Richard P.		
523	Defendant's Rebuttal Expert Disclosures; (Bisordi Depo. Exhibit 1)	Bisordi, William		
524	Bromelain; (Bisordi Depo. Exhibit 13)	Bisordi, William		
525	National Academy of Sciences - Protein and Amino Acids; (Goodman Depo. Exhibit 3)	Goodman, Richard E.		
526	Digestion Absorption of Dietary Protein; (Goodman Depo. Exhibit 5)	Goodman, Richard E.		
527	Chapter- Proteins and Amino Acids; (Goodman Depo. Exhibit 6)	Goodman, Richard E.		
528	Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Correlations of Therapeutic Peptides; (Goodman Depo. Exhibit 7)	Goodman, Richard E.		
529	Trends in Analytical Chemistry: Protein digestomics: "Integrated platforms to study food-protein digestion and derived functional and active peptides."; (Goodman Depo. Exhibit 11)	Goodman, Richard E.		

Exh. No.	Description	Sponsoring Witness	Date Identified	Date Admitted
530	Human a-lactalbumin as a marker of macromolecular absorption; (Pezzone Depo. Exhibit 8)	Pezzone, Michael		
531	Notice of Taking Deposition of Plaintiff Phillip Racies and Request for Production of Documents; (Racies Depo. Exhibit 1)	Plaintiff		
532	Bonnett Fairbourn Friedman & Balint PC correspondence; (Racies Depo. Exhibit 2)	Plaintiff		
533	February 17 2016 response letter to FDA	Underwood, Mark Moran, Daniel Corporate Representative		
534	Ero, MP, A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose.	Bisordi, William		
535	Tachibana, M, A multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling.	Bisordi, William		

Dated: January 3, 2020

CALL & JENSEN
A Professional Corporation

By: /s/ Matthew R. Orr
Matthew R. Orr

Geoffrey W. Castello [Admitted Pro Hac Vice]
Glenn T. Graham [Admitted Pro Hac Vice]
KELLEY DRYE & WARREN LLP

Attorneys for Defendant Quincy Bioscience, LLC

1 Dated: January 3, 2020

BONNETT, FAIRBOURN, FRIEDMAN &
BALINT, P.C.

2
3
4 By: /s/ Patricia N. Syverson
/s/ Patricia N. Syverson

5 Patricia N. Syverson (203111)
6 psyverson@bffb.com
7 Manfred Muecke
8 Mmuecke@bffb.com
9 600 W. Broadway, Suite 900
10 San Diego, CA 92101
11 Telephone: (619) 798-4593

12 BONNETT, FAIRBOURN, FRIEDMAN &
13 BALINT, P.C.
14 Elaine A. Ryan (Admitted Pro Hac Vice)
15 eryl@bffb.com
16 2325 E. Camelback Rd. Suite 300
17 Phoenix, AZ 85016
18 Telephone: (602)-274-1100

19 WELTMAN LAW LLC
20 STEWART M. WELTMAN (Admitted Pro
21 Hac Vice)
22 3841 N. Wayne Ave.
23 Chicago, IL 60613
24 sweltman@weltmanlawfirm.com
25 Telephone: 312-504-1988

26 WILENTZ, GOLDMAN & SPITZER, P.A.
27 Kevin P. Roddy
28 kroddy@wilentz.com
90 Woodbridge Center Drive
Woodbridge, NJ 07095
Telephone: (732) 636-8000

Attorneys for Plaintiff Phillip Racies

CERTIFICATE OF SERVICE

I hereby certify that on January 3, 2020, I electronically filed the foregoing document described as **AMENDED JOINT EXHIBIT LIST** with the Clerk of the Court using the CM/ECF System, which will send notification of such filing via electronic mail to all counsel of record.

/s/ Matthew R. Orr

Matthew R. Orr